biotech news today glp-1 2.0: Where the Next Wave of Value Will Be Created Novartis, Alector, Merck, Alnylm, UniQure

The PREDIMED trial provided participants with approximately 50 ml per day (about one litre per week for household use)

GLP-1 RAs available in 2020 and their pharmacokinetic properties (Table 1) Table 1

Discuss compounded options with your doctor, many are familiar with reputable compounding sources

Some patients may experience transient changes in blood pressure, though long-term cardiovascular outcomes studies have generally shown beneficial or neutral effects of GLP-1 receptor agonists on cardiovascular events

However, it is noteworthy that the larger effect on SBP observed in the SUSTAIN-6 trial (1.3 mmHg and 2.4 mmHg, respectively) compared to ELIXA (0.8 mmHg) may have also contributed to the larger reduction of macroalbuminuria detected in the SUSTAIN-6

Ongoing monitoring of weight loss velocity, blood pressure, heart rate, and symptom burden (palpitations, tremor, insomnia) is standard practice if combination therapy proceeds